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INTRODUCTION
This publication summarizes the latest updates to the 2016 
version of the Italian Guidelines for the management of 
HIV-1 infected patients and the use of antiretroviral drugs 
(Antinori et al., 2016). In particular, in line with the previ-
ous guidelines released in 2016, this version include up-
dated recommendations concerning the following topics: 
estimate of the continuum of care HIV positive individuals 
in Italy, optimal timing and preferred drug combinations 
for starting combined antiretroviral therapy (cART), treat-
ment optimization, and pre-exposure prophilaxis (PrEP). 
Recommendations reported in the Italian Guidelines are 
based upon scientific evidence and expert opinion (Table 
1).
This is a short version of the full text Italian Guidelines for 
the use of antiretroviral drugs and the diagnostic-clinical 
management of people with HIV-1 infection. By definition, 
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this version should not be considered completely exhaustive 
with respect to the full text version of the Guidelines. For a 
complete review of clinical and therapeutic relevant topics 
such as continuum of care, management of comorbidities, 
as well as populations (elderly, women, immigrants, chil-
dren), conditions (drug and/or alcohol addiction, impris-
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SUMMARY
The Italian Society of Infectious and Tropical Diseases (SIMIT) of the Technical Health Committee, Min-
istry of Health (Sections L and M) of Italy have supported recommendations for the Italian guidelines for 
the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. This 
publication summarizes the latest updates to the 2016 version of the Italian Guidelines for the manage-
ment of HIV-1 infected patients and the use of antiretroviral drugs. In particular, new recommendations 
were released concerning the following topics: estimate of the HIV continuum of care in Italy, optimal 
timing and preferred drug combinations for starting antiretroviral therapy, treatment optimization, and 
pre-exposure prophilaxis (PrEP). For a complete review of clinical and therapeutic relevant topics we refer 
the reader to the extended version of the Guidelines. 
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Table 1 - Rating scheme for degree of recommendation (a) 
and level of evidence (b).
a) Degree of recommendation
A Highly recommended
B Moderately recommended
C Optional
b) Level of evidence
Level I The data are obtained from at least one 
controlled, randomized study with sufficient 
power or from a meta-analysis of controlled 
studies.
Level II The data are collated from non-randomized 
studies or from cohort observational studies.
Level III Recommendation based on case reviews or 
agreement among experts.
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onmnet) and transplants requiring special attention we re-
fer the reader to the extended version of the the Guidelines 
(http://www.salute.gov.it/imgs/C_17_pubblicazioni_2442_
allegato.pdf). Similarly, while references cited herein refer 
only to the current update. A complete review of literature 
is available in the extended version of the Guidelines.
Estimate of continum of care in Italy
According to the estimates based on the data collected 
by National Institute of Health (ISS) surveillance sys-
tem and the Icona Foundation Cohort Study, the numbr 
of people living with HIV/AIDS in Italy is 134,000, 11% 
of these being not aware of their condition (Raimondo et 
al. 2016). Out of the 120,000 people who have been diag-
nosed with HIV, 15% have not been linked or maintained 
in care (Mammone et al., 2016), leading to approximately 
102,000 HIV-1 positive persons in care. Based on Icona 
Foundation Cohort data (ICONA 2015), it has been esti-
mated that 83% of people diagnosed with HIV-1 and en-
gaged in care are prescribed antiretroviral therapy and, 
of these, 87% have reached viral suppression (HIV-RNA 
< 50 copies/ml). As a result, in Italy, 74% of people living 
with HIV-1 (99,160 out of 134,000) is receiving cART, and 
52% (69,680 out of 134,000) has achieved viral suppres-
sion. This estimate is consistent with those released by the 
AIDS Operational Centre of the ISS: according to the first, 
obtained applying the model developed by the Joint Unit-
ed Nations Program on HIV/AIDS (UNAIDS), in the year 
2012, 123,000 people were living in Italy, with HIV, 93,000 
of these being precribed cART (Camoni et al., 2014). The 
second, performed over 170 clinical centers in the years 
2012 and 2014, observed a 6.3% increase in the number 
of subjects diagnosed and engaged in care (100,049 vs 
94,146) and an 11,4% increase in the number of patients 
who were prescribed treatment (91,916 vs 82,501) in 2014 
compared to the 2012. Consistent with the recent data, in 
2014, 87.7% of people receiving therapy achieved virolog-
ical suppression (Raimondo et al., 2014).
When to start antiretroviral therapy
The results of two randomized clinical trials (RCT) START 
and TEMPRANO (Insight Start Study Group et al., 2015; 
Temprano ANRS Study Group et al., 2015), emphasize the 
positive impact of early therapy on patients’ global health, 
and the importance of proposing antiretroviral therapy 
to all HIV-1 infected individuals irrespective of their im-
mune-virological status. Thus, the Italian panel strong-
ly recommends initiation of cART in all HIV-1 infected 
adults regardless of their clinical status [AI]. Starting an-
tiretroviral therapy should be related to both clinical ben-
efit and effect of cART on reduction of HIV-1 transmission 
(Treatment as Prevention: TaSP).
Antiretroviral therapy has been shown to significantly re-
duce HIV-RNA in plasma and rectal mucosa, as detected 
by of ultrasensitive assays, in all HIV-infected patients, 
including elite controllers. Similarly, following cART initi-
ation, the levels of immune activation markers and immu-
nological dysfunction significantly decrease in peripheral 
blood as well as in gut tissue. Also for these reasons, early 
initiation of cART is recommended also in elite controllers 
with the aim of reducing the long-term consequences of 
viral replication and chronic inflammation [AI]. 
In patients with opportunistic infections (OIs) for which 
a clinical benefit of prompt treatment initiation is estab-
lished, treatment should be always strongly recommend-
ed and should be started immediately or at least within 2 
weeks (Pneumocystis jiroveci pneumonia, progressive mul-
tifocal leukoencephalopathy, HIV wasting syndrome, HIV 
encephalopathy, Cryptosporidium or Microsporidia enteri-
tis). On the contrary, cART initiation should be delayed for 
those OIs associated with an increased risk of detrimen-
tal effects related to immune reconstitution (criptococcal 
meningitis, tuberculous meningitis, CMV disease, atypical 
mycobacterial infection). In patients with tuberculosis, 
time of treatment initiation should be based on CD4 T cell 
count at diagnosis. Finally, cART should be started con-
comitantly to chemotherapy in all HIV-associated cancers.
Therapeutic regimens in naïve patients
In naïve patients receiving effective cART, complete viro-
logical suppression (decrease of plasma HIV-RNA levels 
below the limit of detection of standard diagnostic tests) is 
achieved within 3-6 months from therapy initiation. Sup-
pression of viral replication is associated with reduction of 
HIV related mortality and morbidity together with immu-
nological recovery and reduction of the inflammatory sta-
tus and of its associated complications. Moreover, suppres-
sion of viral replication has been associated with positive 
effects on the community viral load, with a possible reverse 
of HIV epidemics due to the reduced risk of HIV transmis-
sion, and the de-stigmatization of people living with HIV. 
Thus, because of its direct and indirect effects on patients’ 
life quality and its relevance to public health, rapid suppres-
sion of viral replication must be actively pursued in all HIV 
positive patients.
The choice of a specific pharmacological treatment must 
be based on patients’ individual needs. Several clinical and 
non-clinical factors play a role in determining treatment 
efficacy (Table 2) and they all need to be considered in or-
der to identify the best first regimen for a given patient. 
The standard pharmacological treatment for HIV-1 pa-
tients naïve to therapy usually includes a combination of 
different antiretroviral drugs into the therapeutic regimen. 
Clinical trials, which provide fundamental information for 
the choice of therapy, are usually based on comparison of 
different regimens rather than single drugs. Nevertheless, 
Table 2 - Factors influencing the choice of the first line reg-
imen.
Category Factors
Drugs and drug 
combinations
Virological efficacy
Immunological efficiency
Compactness/convenience
Toxicity and tolerability
Potential drug-drug interaction
Genetic barrier
Extensive clinical use
Clinical practice 
or diagnosis
Presence of an AIDS defining conditions or 
other associated pathologies
Plasma HIV-1 RNA levels
Presence of transmitted resistances
HLA type (presence or absence of 
HLA-B*5701)
Non-clinical Assessment of patient’s willingness and 
readiness to start treatment
Population specific characteristics
Particular conditions
For a more detailed description of the single factors influencing the choice of the 
first regimen we refer the reader to the last edition of the Italian guidelines for the 
treatment of HIV-1 infected patients.
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for the choice of an appropriate drug combination is man-
datory to consider also the information concerning the 
properties of the single molecules included in the regimen.
For treatment initiation in acute or recent infections (e.g. 
within 6 months from possible viral transmission or acute 
retroviral syndrome), current HIV guidelines agree to rec-
ommend the use of an antiretroviral regimen demonstrat-
ed to be effective in presence of high viral load (HIV-RNA 
>100,000 copies/ml) [AII]. Despite the lack of evidences 
deriving from clinical trials, in patients with acute or re-
cent infection carrying extremely high baseline viral loads 
(HIV-RNA >500,000 copies/ml), infectious diseases spe-
cialists might favor a transitory regimens with four differ-
ent drugs including an integrase inhibitor and a protease 
inhibitor [CIII] until the resistance test (GRT) is not avail-
able.
Given the fact that current cART needs to be taken life-
long, it seems appropriate to implement the first regimen 
Table 3a - Antiretroviral regimens recommended for starting cART.
Regimen
Degree of 
recommendation/
Level of evidence
References
Recommended regimen options (for all conditions)
TDF/FTC + RAL [AI] Lennox et al., 2009; Raffi et al., 2013a; Raffi et al., 2013b;
Rockstroh et al., 2013; Lennox et al., 2014; 
TAF/FTC + RAL [AII] Lennox et al., 2009; Raffi et al., 2013a;  
Raffi et al., 2013b; Rockstroh et al., 2013; 
Lennox et al., 2014; Wohl et al., 2015; Gallant et al., 2016; 
TDF/FTC/EVG/COBI [AI] DeJesus et al., 2012; Sax et al., 2012; 
Clumeck et al., 2014; Wohl et al., 2014; Squires et al., 2015
TAF/FTC/EVG/COBI [AI] Sax et al., 2015; Wohl et al., 2016;
TDF/FTC + DTG [AI] Raffi et al., 2013a; Raffi et al., 2013b; Clotet et al., 2014
TAF/FTC+DTG [AII] Data from studies in naïve patients are not available
ABC/3TC + DTG [AI] Raffi et al., 2013a; Raffi et al., 2013b;  
Walmsley et al., 2013; Clotet et al., 2014
ABC/3TC/DTG [AI] Raffi et al., 2013a; Raffi et al., 2013b; 
Walmsley et al., 2013; Clotet et al., 2014; Weller et al., 2014
TDF/FTC/RPV 
(for patients with HIV-RNA <100.000 cp/ml and CD4 
T cell count >200 cells/μl)
[AI] Molina et al., 2011; Cohen et al., 2012; 
Cohen et al., 2013a; Cohen et al., 2014
TAF/FTC/RPV
(for patients with HIV-RNA <100.000 cp/ml and CD4 
T cell count >200 cells/μl)
[AII] Data from studies in naïve patients are not available
Recommended regimen options (for particular conditions)
TDF/FTC+ATV+r or TDF/FTC+DRV+r 
(recommended in individuals with uncertain 
adherence or in patients who need to begin treatment 
before resistance testing results are available)
[AII] Ortiz et al., 2008; Molina et al., 2010; Daar et al., 2011; 
Soriano et al., 2011; De Jesus et al., 2012; 
Gallant et al., 2013; Orkin et al.. 2013; Clotet et al., 2014; 
Clumeck et al., 2014; Lennox et al., 2014; Mills et al., 2015a
TAF/FTC+ATV+r or TAF/FTC+DRV+r 
(recommended in individuals with uncertain 
adherence or in patients who need to begin treatment 
before resistance testing results are available)
[AII] Ortiz et al., 2008; Molina et al., 2010; Daar et al., 2011; 
Soriano et al., 2011; DeJesus et al., 2012; 
Gallant et al., 2013; Orkin et al., 2013; Clotet et al., 2014; 
Clumeck et al., 2014; Lennox et al., 2014; Mills et al., 2015a
TDF/FTC+ATV/COBI or TDF/FTC+DRV/COBI
(recommended in individuals with uncertain 
adherence or in patients who need to begin treatment 
before resistance testing results are available)
[AII] Tashima et al., 2014; Gallant et al., 2015
TAF/FTC+ATV/COBI or TAF/FTC+DRV/COBI
(recommended in individuals with uncertain 
adherence or in patients who need to begin treatment 
before resistance testing results are available)
[AII] Tashima et al., 2014; Gallant et al., 2015
- NNRTI based regimens are not recommended in presence of mutations conferring resistance to NRTI and NNRTI.
- Because of the possible occurrence of hypersensitivity reactions (HSR), ABC is not recommended in subjects harbouring the HLA allele B*5701.
- COBI is not recommended in patients with impaired renal function (GFR <70 ml/min/1.73 m2). Follow up data about tubular toxicity are limited. The combination EVG/
COBI/FTC/TAF is a therapy option for patients with eGFR>30 ml/min.
- TAF/FTC backbone, once available, is to be considered the preferred choice in switching from TDF/FTC. TAF/FTC only for patients with eGFR>30 ml/min.
- Regimens including TDF/FTC + ATV/r, ATV/COBI, DRV/r, or DRV/COBI are recommend [AII] only for the above mentioned conditions. In all the other cases, they should 
be considered as alternative regimens [BI].
- DRV/r dosage is 800/100 mg once a day. 
- A TAF dose of 10 mg when used in combination with PK boosters (ritonavir or cobicistat) and 25 mg in unboosted regimens.
- Risk of hyperbilirubinemia and hyperbilirubinemia-associated adverse effects needs to be considered before prescribing ATV/r and ATV/COBI. 
- The regimen TDF/FTC/RPV is not licensed for patients with HIV-1 plasma RNA>100000 copies/ml. TAF/FTC/RPV is a therapy option for patients with eGFR >30 ml/min.
- Regimens including COBI are not recommended for treatment of pregnant patients.
- TAF/FTC/RPV is a therapy option for patients with eGFR >30 ml/min.
“/”=co-formulated; “+”=not co-formulated.
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according to a stepwise strategy, in which a therapeutic 
combination providing a strong and rapid reduction of 
viral load (in order to achieve the goals resulting from re-
duction of viral replication), is followed by an optimized 
regimen, tailored to maintain viral suppression while bet-
ter matching the present and future needs of the patient 
(See chapter 3, Treatment Optimization).
Classification and degree of recommendation  
of cART regimens for the treatment of antiretroviral 
(ARV)-naïve patients
Recommended regimen options (for all conditions)  
(Table 3a)
The present document recommends, for all conditions, ten 
ARV regimens, eight based on integrase strand transfer inhib-
itors (INSTI) and two based on non-nucleoside reverse tran-
scriptase inhibitors (NNRTI). The two recommended NNR-
TI-based regimens (tenofovir disoproxil fumarate (TDF) or 
tenofovir alafenamide (TAF)/emtricitabine (FTC)/rilpivirine 
(RPV) are indicated for cART initiation only in patients with 
HIV-RNA <100,000 copies/ml and CD4 T cell count >200 cell/
µl, according to regulatory limitations approved.
In all these ten recommended regimens, the backbone nu-
cleoside consists of a combination of FTC and TDF or TAF, 
except for the combination of abacavir (ABC) and lamivu-
dine (3TC) that is recommended only in combination with 
the INSTI dolutegravir. Five out of these ten regimens are 
available as single tablet regimen (STR).
All these recommended regimens meet all the following 
criteria:
– Proven efficacy in RCT with sufficient potency (quality, 
numerosity, adequacy of control groups). In particu-
lar, recommended antiretroviral regimen must demon-
strate non-inferiority over another already recom-
mended regimen and meet at least one of the following 
conditions:
- Demonstrated superiority compared to at least one 
alternative regimen;
- Better tolerability and non-inferiority compared to a 
recommended regimen;
– Favourable acceptability, tolerability, and safety pro-
files;
– Well established clinical use demonstrated by the num-
ber and duration of clinical trials, by the data deriving 
from observational studies, or by the extensive use in 
clinical practice after their introduction to the market.
Recommended regimen options for particular 
conditions (Table 3b)
Eight different boosted-protease inhibitors (PI)-based 
regimens, including boosted atazanavir or darunavir (en-
Table 3b - Alternative drugs combinations for first-line regimens.
Regimen
Degree of 
recommendation/
Level of evidence
References
TDF/FTC/EFV or TDF/FTC+EFV [BI] DeJesus et al., 2004; van Leth et al., 2004; 
Gallant et al., 2006; Arribas et al., 2008; Riddler et al., 2008; 
Sax et al. 2009; Post et al., 2010; Lennox et al., 2009; 
Daar et al., 2011; Molina et al., 2011; Sax et al., 2012; 
Cohen et al., 2013a; Nelson et al., 2013; 
Rockstroh et al., 2013; Walmsley et al., 2013; 
Carey 2014; Cohen et al., 2014; Wohl et al., 2014
TAF/FTC+EFV [BII] Data from studies in naïve patients are not available
ABC/3TC+EFV
(recommended if plasma HIV-1 RNA<100,000 copies/
ml) 
[BI] Sax et al., 2009; Post et al., 2010; Daar et al., 2011; 
Sax et al., 2011
ABC/3TC+ATV/r
(recommended if plasma HIV-1 RNA<100,000 copies/
ml)
[BI] Sax et al., 2009; Daar et al., 2011; Sax et al., 2011
ABC/3TC+ATV/COBI 
(recommended if plasma HIV-1 RNA<100,000 copies/
ml)
[BIII] Sax et al., 2009; Daar et al., 2011; Sax et al., 2011; 
Ramanathan et al., 2009
ABC/3TC+DRV/r [BII] Clotet et al., 2014
ABC/3TC+DRV/COBI [BIII] Clotet et al., 2014; Kakuda et al., 2014
ABC/3TC+RAL [BII] Raffi et al., 2013a
DRV/r + RAL 
(Recommended if CD4 T cell count >200 cells/
µl; caution must be used when prescribing this 
combination in patients with HIV-1 RNA viral load 
>100,000 copies/ml)
[BI] Raffi et al., 2014
- NNRTI based regimens are not recommended in presence of mutations conferring resistance to NRTI and NNRTI.
- The standard dosage of EFV is 600 mg/once a day. The off label dosage of 400mg once a day proved to be not inferior to standard dosage if prescribed in 
association with TDF/FTC.
- Because of the possible occurrence of hypersensitivity reactions (HSR), ABC is not recommended in subjects harbouring the HLA allele B*5701.
- DRV/r dosage is 800/100 mg once a day.
- Risk of hyperbilirubinemia and hyperbilirubinemia-associated adverse effects needs to be considered before prescribing ATV/r and ATV/COBI.
- COBI is not recommended in patients with impaired renal function (GFR <70 ml/min/1.73m2). Follow up data about tubular toxicity are limited.
- Regimens including COBI are not recommended for treatment of pregnant patients
“/”=co-formulated; “+”=not co-formulated.
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hanced by low-dose ritonavir or cobicistat), both com-
bined to TDF/FTC or TAF/FTC as backbone nucleoside, 
are now recommended in particular conditions (patients 
with uncertain adherence, patients who need to begin 
treatment before resistance testing results are available, 
or for therapy initiation in pregnant women).
All these regimens, although not fulfilling all the crite-
ria for recommended regimens, can be considered as 
preferable therapeutic options because of proven ben-
efits in terms of efficacy, genetic barrier, tolerability, 
and safety. 
For pro and cons of single drugs and drug combinations 
taking in account information concerning tolerability 
and toxicity, pharmacological interactions, formulations, 
posology, we refer the reader to the complete version of 
the Italian Guidelines.
Treatment optimization
Drugs reduction
The goal of this treatment scheme, named Less Drug Reg-
imen (LDR), is to reduce the number of antiretroviral 
drugs included in a given regimen by applying an induc-
tion-maintenance therapeutic strategy. In the first phase, 
viral suppression is achieved trough a standard triple an-
tiretroviral regimen. Then, once plasma viral load is not 
detectable anymore and immunoreconstitution is taking 
place (at least 6 months after achieving viral suppression), 
treatment could be safely switched to a LDR. The aim of 
this therapeutic approach is to limit or prevent long-term 
toxicities, increase tolerability and reduce pharmacolog-
ical interactions, while maintaining virological control. 
Of note, benefit in terms of reducing possible drug-drug 
interactions is of particular interest given the aging of the 
Table 4 - Summary of rationale and advantages/disadvantages of dual therapy for treatment optimization.
Class of 
optimization Aims
Additional potential 
advantages Potential disadvantages
Degree of 
recommendation/
Level of evidence
References
From a triple drug 
combination to 
ATV/r or ATV/c + 
3TC 
Reduce/
Prevent NRTI 
associated 
toxicity.
Virological efficacy 
non-inferior or 
superior (when 
switching from 
ATV/r+TDF/FTC) 
to triple drug 
combination 
prosecution.
Possible increased of PI 
associated toxicity 
[AI] in patients 
experiencing 
toxicity induced 
by NRTIs 
different from 
3TC/FTC or [BI] 
as a preventive 
measure
Perez-Molina et al., 
2015;
Arribas et al., 2015; 
Di Giambenedetto 
et al., 2015
From a triple drug 
combination to 
DRV/r or DRV/c
Reduce/
Prevent NRTI 
associated 
toxicity.
Virological 
efficacy in subjects 
not eligible for 
simplification to 
monotherapy.
Possible increased of PI 
associated toxicity
[AI] in patients 
experiencing 
toxicity induced 
by NRTIs 
different from 
3TC/FTC or [BI] 
as a preventive 
measure
Fabbiani et al., 
2016, Pulido et al., 
2016; Ciaffi et al., 
2016
From a triple drug 
combination to 
DRV/r or DRV/c + 
RPV (a) 
Reduce/
Prevent NRTI 
associated 
toxicity
Limited long term data 
on efficacy. Possible 
development of NNRTI 
resistance (ETR included) in 
case of failure.
[BI/CI] Maggiolo et al., 
2016
From a triple drug 
combination to 
DRV/r or DRV/c + 
RAL(b)
Reduce/
Prevent NRTI 
associated 
toxicity
Limited long term data 
on efficacy. Development 
of InSTI resistance (DTG 
included) in case of failure.
[CII] Madeddu et al., 
2015; Calza et al., 
2016; 
From a triple drug 
combination to 
DTG + RPV (c)
Reduce/
Prevent NRTI 
associated 
toxicity
PI toxicity savings Limited long term data 
on efficacy. Possible 
development of InSTI and 
NNRTI resistance in case of 
failure
[CII] Capetti et al., 2016; 
Diaz et al., 2016; 
Palacios et al., 2016
From a triple drug 
combination to 
DTG + 3TC (d)
Reduce/
Prevent NRTI 
associated 
toxicity
PI toxicity savings Limited long term data 
on efficacy. Possible 
development of InSTI (DTG 
included) and 3TC resistance 
in case of failure
[CII] Maggiolo et al., 
2016; Baldin et al., 
2016; Reynes et al., 
2016
a): Randomized Pilot Study 1: 1, 60 patients with virologic suppression; virologic response at 48 weeks (snapshot analysis): 96.7% in the DRV/r +RPV vs 
93.4% in the control arm (triple continuation PI+NNRTI) (Maggiolo et al., 2016).
b): Two uncontrolled studies; the first including 82 patients in virologic suppression: 92.7% of patients with HIV-1 RNA <50 copies/mL at 48 weeks (Calza 
et al., 2016); the second including 72 patients with virologic suppression; probability of treatment failure (virologic failure or discontinuation for any 
reason): 13% at 12 months, 22% at 24 months (Madeddu et al, 2015).
c): Evidences derived from three uncontrolled trials; In the first trial, which included 132 patients experiencing virological failure or virologic suppression; 
98% of the 50 participants who reached week 48 had HIV-1 RNA<50 copies/mL (Capetti et al., 2016); in the second trial, which included 38 virologically 
suppressed patients, 92% of participants maintained virologic suppression at 48 weeks (Diaz et al., 2016). Finally, the third trial enrolled 104 patients, 
80% them virologically suppressed at the time of trial initiation. Out of 85 patients who reached week 24 of follow-up, 97% had HIV-1 RNA <50 copies/
ml (Palacios et al., 2016).
d): Three uncontrolled trials; the first including 68 patients with virologic suppression; no virologic failure at 24 weeks (Maggiolo et al., 2016); the second 
including 105 patients in virologic suppression; after 6 months 10 patients had discontinued treatment and 2 had a virologic failure (Baldin et al., 2016); 
the third including 27 patients in virologic suppression; no virologic failure at 48 weeks (Reynes et al., 2016).
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HIV population and the use of concomitant medications 
for management of comorbidities.
The following paragraphs describe the current therapeu-
tic scenario for switching to LDR in cART treated patients 
with viremia below the detection limit. To give a broaden 
overview of all the possible therapeutic strategies, drug 
combinations are described regardless of the specific indi-
cations provided in the technical datasheets.
Dual therapy (Table 4)
Dual therapy regimens were developed with the aim of 
reducing or excluding the use of nucleoside reverse tran-
scriptase inhibitors (NRTIs), since these drugs show high 
long-term toxicities. In particular, it has been suggested 
that the main benefit of dual therapy is the reduced risk 
of renal and bone toxicity usually associated with the use 
of TDF. Whether dual therapy will be less relevant after 
the introduction in clinical practice of TAF, which shows 
a better toxicity profile compared to TDF, remains to be 
assessed.
Since lopinavir/ritonavir based regimens are no longer rec-
ommended due to the high toxicity and low convenience 
(pill burden, gastro-intestinal tolerability and increased 
cardiovascular risk), the only PI-based regimens recom-
mended are DRV and ATV-based dual combinations. The 
evidences for effectiveness of ATV/c or ATV/r+3TC and 
DRV/c or DRV/r+3TC are based on RCT and are sufficient-
ly strong to allow a recommendation level [AI] for toxicity 
reduction and [BI] for NRTI toxicity prevention.
For DRV/c or DRV/r+RPV, although performed on a lim-
ited number of patients, randomized studies provide 
enough statistical power provide to grant a recommenda-
tion level [BI] for the reduction of toxicity and optional 
[CI] for the prevention of toxicity. The evidences for effec-
tiveness of DRV/c or DRV/r+RAL are based on one study 
without control arm; however, the efficacy of this combi-
nation has been proved in a RCT enrolling naive patients, 
for whom it can be considered a recommended alternative 
regimen. All togheter these data give an optional recom-
mendation level [CII]. Current evidences for effectiveness 
of DTG+3TC and DTG+RPV are based on few patients.
The results of the two SWORD studies, have been recently 
announced (Llibre et al., 2017). However, since the publi-
cation of the Italian Guidelines is dated November 22th, 
2016, these data were not included in the present work.
Boosted protease inhibitors (PI) monotherapy  
(Table 5).
Improvement of toxicity profile together with reduction of 
treatment costs are the main advantages supporting the 
switch to boosted-PI monotherapy in suppressed patients. 
Consistently, several studies have evaluated the switch 
from a standard therapeutic regimen to a monotherapy 
consisting of a PI/r.
The PIVOT study evaluated the performances of mono-
therapy with PI/r compared to the conventional triple 
therapy; primary endpoint was loss of future treatment 
options based on development of drug resistance. After 
3.5-years of follow up, this study indicated that mono-
therapy with PI/r is associated with 35% risk of virological 
failure (vs 3% of patients in triple treatment arm), does 
not induce clinical events, promotes a slight reduction of 
grade 3-4 adverse events (46% vs 55%, p=0,04), does not 
reduce the range of therapeutic options available for fu-
ture switching, and has a favourable cost-effect profile.
A recent meta-analysis evaluating efficacy of DRV/r or 
LPV/r in several RCTs (n=1553) estimated a -7% differen-
tial difference (95% CI:-11% -4%) for the occurrence of 
virological failure between patients switching to mono-
therapy with PI/r and patients maintaining standard triple 
therapy (reintroduction of NRTI backbone was considered 
as virological failure). If return to previous regimens was 
not considered as failure, the estimated difference be-
tween the two arms was 0% (95%CI -3% +3%).
It should be noted that the only RCT evaluating ATV/r 
monotherapy (MODAT) was interrupted due to virological 
inferiority at 48 weeks compared to triple therapy. Simi-
larly, the prolonged 96 weeks analysis did not demonstrate 
non-inferiority (efficacy: 64% ATV/r monotherapy vs 63% 
ATV/r+2NRTI, difference +1.3%; 95% CI: -17.5%-20.5%) 
(Spagnuolo et al., 2014)
Identification of variables associated with virological fail-
ure after switch to PI/r monotherapy is of interest in view 
of their possible application as predictors of efficacy after 
treatment change in switching strategies. Several vari-
ables, including low nadir CD4 T cell count, low therapy 
Table 5 - Summary of rationale and advantage/disadvantages of monotherapy for treatment optimization.
Class of 
optimization Aims 
Potential 
disadvantages
Degree of 
recommendation/
Level of evidence
Referencese
From dual or 
triple therapy to 
DRV/r o DRV/c 
800/100 mg QD
Reduce/
Prevent 
NRTI 
associated 
toxicity.
Reduced virological 
efficacy (non inferior 
in patients with 
nadir CD4 T cell 
counts >200 cells/
µl); contraindicated 
in HBsAg positive 
patients.
[BI] in patients 
experiencing 
toxicity induced 
by NRTIs or [CI] 
as a preventive 
measure 
Cameron et al., 2008; Arribas et al., 2009; 
Bierman et al., 2009; Pulido et al., 2009; 
Gutmann et al., 2010; Cahn et al., 2011b; Arribas et al., 2012;
Valantin et al., 2012; Arribas et al., 2014a; 
d’Arminio Monforte et al. 2014; Gianotti et al., 2014; 
Pinnetti et al., 2014; Paton et al., 2015
Antinori et al., 2015; Pinnetti et al., 2014; 
Geretti et al., 2016; Gianotti et al., 2016
From dual or 
triple therapy to 
ATV/r o ATV/c 
300/100 mg QD
Reduce/
Prevent 
NRTI 
associated 
toxicity.
Reduced virological 
efficacy, especially 
in patients HIV/HCV 
co-infected and in 
patients with HIV-1 
RNA >100000 cp/
ml before starting 
cART; contraindicated 
in HBsAg positive 
patients.
[CI] in patients 
experiencing 
toxicity induced 
by NRTIs or not 
reccomended 
as a preventive 
measure
Spagnuolo et al., 2014; Swindells et al., 2006; 
Karlström et al., 2007
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adherence, as well as limited duration of either the previ-
ous antiretroviral treatment or the viral suppression were 
all associated with an increased risk of failure in RCTs, 
observational studies and meta-analysis. Among these 
variables, nadir CD4 T cell count proved to be the most ac-
curate parameter predicting virological failure. Increased 
risk of failure was associated with nadir CD4 T cell counts 
<100 cells/µl with LPV/r monotherapy, and to nadir CD4 T 
cell counts <200 cells/µl with LPV/r and DRV/r monothera-
py. These observations support the application of a thresh-
old of nadir CD4 T cell count above 200 cells/µl to select 
HIV-1 patients eligible for DRV/r or LPV/r monotherapy.
Concomitant HCV infection was suggested as a factor as-
sociated to virological failure during monotherapy by the 
MODAT and MONET studies, which evaluated the effect 
of switch to monotherapy with ATV/r and DRV/r, respec-
tively. However, other studies based on DRV/r monother-
apy such as the MONOI, PROTEA and PRIMO trials, as 
well as the studies including LPV/r, all failed to confirm 
this association and do not support the use of HIV/HCV 
coinfection as a predictor for PI/r monotherapy response. 
In the MONOI and MONET studies, other additional fac-
tors able to predict virological failure of DRV/r monother-
apy were identified, such as HIV-1 viremia based on a ul-
Table 6 - Summary of rationale and advantage/disadvantages regimens with reduced doses/administration (including FDC and 
STR).
Class of 
optimization Aims
Additional potential 
advantages
Potential 
disadvantages
Degree of 
recommendation/
Level of evidence
References
From NVP + 2 
NRTI and from 
EFV + 2 NRTI 
to TDF/FTC/
RPV (a)
Improvement 
of adherence 
or toxicity 
reduction
Lower metabolic impact 
and improvement of EFV 
associated neurological 
symptoms.
Slight reduction of 
eGFR (uncertain 
clinical relevance).
[BII] Mills et al., 2013;
Allavena et al., 2014; 
Mora-Peris et al., 2014; 
Gianotti et al., 2015; 
Cazanave et al., 2015; 
Pinnetti et al., 2015
From NNRTI 
to EVG/COBI/
FTC/TAF (b) 
or EVG/COBI/
FTC/TDF (c)
Reducing 
toxicity.
Lower incidence of 
CNS adverse events; 
slight improvement of 
metabolic profile
Slight reduction of 
eGFR, but limited 
when using TAF 
(uncertain clinical 
relevance).
[AI] Pozniak et al., 2014; 
Mills et al., 2015b; 
Mills et al., 2015c; 
Mills et al., 2016 
Pozniak et al., 2016; 
From PI/r to 
RPV/TDF/FTC 
(d)
Reducing 
toxicity.
Lower incidence of 
gastrointestinal adverse 
effects; Lower metabolic 
impact
Lower genetic barrier. [AI] Palella et al., 2014; 
Giannotti et al., 2015; 
From PI/r or 
PI/c to EVG/
COBI/FTC/TAF 
(c,e) or EVG/
COBI/FTC/TDF 
(f)
Reducing 
toxicity.
Increased virological 
success, improved 
patient satisfaction, 
minor adverse events. 
Proteinuria reduction and 
improvement in BMD.
Slight reduction of 
eGFR, but limited 
when using TAF 
(uncertain clinical 
relevance). Lower 
genetic barrier.
[AI] Mills et al., 2016; 
Pozniak et al., 2016; 
Arribas et al., 2016
From all 
regimens to 
DTG/ABC/3TC 
(g)
Reducing 
toxicity
Increased patient 
satisfaction.
Cardiovascular 
toxicity derived 
from the use of ABC 
cannot be ruled out; 
increased number of 
adverse events.
[BI] Fantauzzi et al., 2015; 
Lake et al.,
2016
From LPV/r to 
ATV/r or ATV/c. 
From LPV/r to 
DRV/r or ATV/r 
once daily
Reducing 
specific 
toxicity
Lower impact on 
lipid metabolism and 
gastrointestinal adverse 
effects. Reduced pill 
burden.
ATV increases 
the risk of 
hyperbilirubinemia.
[AII] Gatell et al., 2007; 
Mallolas et al., 2009; 
Ucciferri et al., 2013
a) Although RCTs are missing, observational studies showed a low risk of virological failure in virologically suppressed patients switching to RPV/FTC/
TDF STR
b) A randomized clinical trial including 434 patients the simplified regimen STR EVG/COBI/FTC/TDF was compared to standard NNRTI based antiret-
roviral regimens. At week 48, simplification arm showed virological non-inferiority (93% vs 88%), minor CNS disorders, and a tendency to an increase 
eGFR and a lower metabolic impact compared to the control group.
c) Switching to TAF based therapies limits kidney toxicity and can be considered as a therapeutic choice in patients experiencing renal insufficiency. 
Furthermore, TAF proved to have superior virological success (GS-109 Study).
d) In the SPIRIT study, 476 virologically suppressed HIV-1 patients were randomized (2:1) to switch to TDV/FTC/RPV immediately or at week 24. Non 
inferiority of the simplification from PI to RPV was demonstrated at 24 weeks together with a slight increase of eGFR and in an improvement of lipid 
profile. At week 48, 89.3% of the simplified RPV group maintained viral suppression. Additional observational studies failed to identify significant risk 
of virological failure in patients with no history of previous resistance or risks of toxicity.
e) The GS-109 study (RCT including 601 patients from ATV/r + FTC/TDF to EVG/COBI/FTC/TAF FDC) demonstrated a superior virological success at week 
48, improvement of bone mineralization and kidney and tubular functionality together with a slight impairment of the lipid profile whose long term 
clinical implications need to be assessed.
f) One randomized clinical trial including 433 STR patients simplified to EVG/COBI/FTC/TDF showed superiority in virologic suppression at week 48 of 
the simplified group compared to the control group with PI based antiretroviral (94% vs 87%); moreover simplified patients had a significant improve-
ment in quality of life and reduced, in particular, gastrointestinal adverse events.
g) One randomized clinical trial including 551 patients who switched to a simplified STR regimen DTG/ABC/3TC showed non-inferiority in virologic 
efficacy at week 48 of the simplified group compared to the control group with unchanged antiretroviral therapy. Although patients included in the 
simplification group showed an improvement in the degree of patient satisfaction, this study arm showed a greater number of adverse events leading 
to discontinuation of treatment.
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trasensitive assay (HIV-RNA >1 copy/ml o >5 copies/ml) 
and HIV-1 DNA levels at baseline.
Increase in viral replication in cerebrospinal fluid (CSF) 
was sporadically reported among patients enrolled in 
MOST, MONOI and MONET studies, leading to the hy-
pothesis of a possible association between PI/r monother-
apy and an increasing risk HIV-1 replication in the CSF 
and of neurocognitive impairment. However, in the PRO-
TEA trial, no case of developing HIV-1 viraemia in CSF 
was observed in patients with a CD4 T cell nadir >200 cell/
µl. Moreover, the analysis of the tree RCTs (PIVOT, PRO-
TEA and MODAT) in which neurocognitive assessment 
was included in the trial evaluation scheme, did not con-
firm the existence of an increased risk of neurocognitive 
impairment during PI/r monotherapy.
In light of the above mentioned studies, switching to 
DRV/r monotherapy can be moderately recommended in 
presence of NRTI associated toxicity [BI]. Moreover, it can 
represent an acceptable option to prevent NRTI associated 
toxicity [CI] in selected patients treated with PI, who have 
no history of virological failure to PI, no PI resistance as-
sociated mutations, suppressed viremia (viral load below 
50 copies/ml) for at least 12 months, and a nadir T CD4 
cell count >200 cells/µl, and have no previous history of 
central nervous system associated adverse events.
Viral load monitoring every 3 months for the early identifi-
cation of possible failures, and implementation of period-
ic strategies to monitor patient adherence [AIII] are gen-
erally recommended in patient undergoing monotherapy 
treatment with protease inhibitors. In case of virological 
rebound (two consecutive values higher than 50 copies/
ml) a resistance test, performed on plasma HIV-1 RNA 
[AIII] and proviral DNA [CIII], followed by resumption of 
triple therapy [AIII] are recommended. 
Pill burden reduction (Table 6)
Different therapeutic approaches have been developed 
in order to reduce the regimen complexity and promote 
the adherence including once daily regimens, fixed dose 
combinations (FDC) and single tablet regimens (STR). 
FDC are combinations of two or more active drugs in a 
fixed ratio of doses, which are preferred over non-stan-
dardized combinations. 
FDC may be administered as single products given con-
currently or coformulated in one table, such as in STRs. 
cART adherence might be increased using regimens 
which involve a pill burden reduction by FDC or STR, 
and daily intake (QD) of medications.
Switching from PI to a different antiretroviral class (NN-
RTI or INSTI), i.e. from a regimen with a very high ge-
netic barrier to a regimen with a lower genetic barrier, is 
recommended to improve therapy tolerability. It must be 
noted that this therapeutic choice is appropriate only for 
patients who have never experienced virological failure, 
have never been exposed to suboptimal concentrations of 
NRTIs, and do not present mutation associated with NRTI 
Table 7 - Summary of rationale and advantages/disadvantages of other optimization strategies.
Class of 
optimization Aims
Additional potential 
advantages Potential disadvantages
Degree of 
recommendation/
Level of evidence
Literature
From FTC/
TDF to FTC/
TAF
Prevention 
or reduction 
of specific 
toxicity.
Effective 
Maintenance of 
efficacy.
Lower impact on 
renal toxicity.
Lower impact on 
bone turn over.
Slight worsening of the lipid profile, 
whose clinical implications in the 
long term still pending
[AI] Mills et al., 2013; 
Pozniak et al., 2015; 
Raffi et al., 2016;
Mills et al., 2016;
From EFV/
FTC/TDF or 
RPV/FTC/
TDF to RPV/
FTC/TAF
Prevention 
or reduction 
of toxicity.
Proteinuria 
reduction. BMD 
improvement. 
Improvement of 
neuropsychiatric 
disorders when 
switching from 
EFV/FTC/TDF
[AI]
Orkin et al. 2016
From PI/r or 
PI/c to RAL 
(a)
Reduction of 
toxicity.
Lower 
gastrointestinal 
disorders; lower 
metabolic impact
Lower genetic barrier, non-
inferiority not reached in a study, 
RAL BID regimen (at least until 
the approval of the RAL QD 
formulation), not recommended in 
case of previous failures to NRTIs. 
The strategy is eventually to be 
performed after at least 6 months 
of virologic suppression.
[BI] Eron et al., 2010; 
Martínez et al., 2007; 
Curran et al., 2012
From ATV/r 
to ATV (b)
Reduction 
of specific 
toxicity.
Hyperbilirubinemia 
Reduction. Modest 
reduction in lipids, 
fewer side effects.
Lower genetic barrier, not to be 
co-admistred with with TDF and 
anti-acids
[CII] Ghosn et al., 2010; 
Squires et al., 2012
a) A randomized study that analyzed the switch from LPV/r to RAL in patients with virologic suppression did not reached the virological non-inferiority. 
The main cause of failure was the presence of previous virologic failures and therefore the likely resistance to NRTIs. A second randomized study 
instead demonstrated non-inferiority virological, presumably thanks to a longer period of previous virologic suppression before the switch, of at least 
6 months. Both studies also demonstrated a favorable impact on blood lipids; furthermore, in the SPIRAL study the switch to RAL has significantly 
reduced the use of statins and increased bone density.
b) Indicated in patients with intolerance to ritonavir and contraindications to cobicistat. Not recommended in case of co-administration of tenofovir or anti-
acid drugs. In this case, if it is necessary - for toxicity - ritonavir interruption, the ATV plasma concentration must be periodically verified through TDM.
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resistance (and NNRTI if the switch involves this class of 
drugs) [AI]. Moreover, a minimum of 6 months of virolog-
ical suppression is required to switch to a regimen includ-
ing RAL. Concerning the switch from a PI/r- based reg-
imen to STR of EVG/COBI/FTC/TDF or EVG/COBI/FTC/
TAF, a higher efficacy at 48 weeks compared to PI/r-con-
tinuing control arm has been proven. Finally, while data 
from RCTs are available to support the switch from reg-
imens containing EFV to STR based on INSTI [AI], the 
switch from regimens containing EFV to STR based on 
TDF/FTC/RPV has been evaluated only in observational 
studies that nevertheless showed no risk of virological fail-
ure or toxicity [BII].
Other optimization strategies
We refer the reader to Table 7.
The use of anti HCV drugs for the therapeutic 
management of HIV/HCV infected patients 
Treatment with direct acting antivirals (DAAs) should be 
considered for all HIV-1 infected patients with chronic 
hepatitis virus infections. 
The following reasons support the eradication of HCV in-
fection in all HIV/HCV co-infected patients:
– Progression of liver disease results in higher mortality 
rates due to hepatocarcinoma and unbalanced cirrhosis
– Proven negative impact of HCV infection:
- Reduced kidney functionality and increased mortali-
ty unrelated to liver disease 
- Impaired CD4 T cell recovery during c-ART
– Possible negative impact of HCV infection on:
- HIV-1 progression even in presence of c-ART
- Osteoporosis
- Cardiovascular diseases
- Onset of diabetes.
HCV eradication is associated with a lower likelihood of 
unbalanced liver disease and with reduced mortality rates 
in patients with advanced liver disease, as well as in pa-
tients with moderated fibrosis.
Pre-Exposure Prophylaxis 
The pre-exposure prophylaxis (PrEP) with the combina-
tion of TDF/emtricitabine (FTC), in a continuous (daily) 
or intermittent (“on demand”) is currently recommended 
as effective for the prevention of HIV-1 transmission [AI 
in people at high risk of acquiring HIV-1 infection- Effi-
cacy was demonstrated in both controlled clinical studies 
and in their “open” extensions as well as in other obser-
vational studies. The studies, performed also in Europe, 
demonstrate that the effectiveness of the PrEP in prevent-
ing HIV-1 infection is strongly correlated with adherence 
to treatment, and adherence to PrEP protocol should be 
considered as a critical issue for PrEP success [BII] (Grant 
et al., 2010; Molina et al., 2015; McCormack et al., 2016; 
Hanscome et al., 2016; Funner et al., 2016; Spinner et al., 
2016; Sagaon-Teyssier L et al., 2016). Based on available 
evidences (Centers for Disease Control and Prevention, 
2014; World Health Organization, 2016), specific guide-
lines have been issued, and the European Commission on 
Recommendation of the Committee for Medicinal Prod-
ucts for Human Use (CHMP) of the European Medicines 
Agency (EMA) granted the extension of a business in the 
28 European Union countries for FTC + TDF as PrEP (Eu-
ropean Medicines Agency, 2016a; European Medicines 
Agency, 2016b). 
Authorized by the Ministry of Health. In collaboration with 
the Sections L and M of the Technical Health Committee, 
Ministry of Health. Issued by the Italian Society of Infec-
tious and Tropical Diseases (SIMIT). 
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